Aditxt, Inc. (ADTX)
NASDAQ: ADTX · IEX Real-Time Price · USD
1.465
-0.115 (-7.28%)
At close: Jul 2, 2024, 3:59 PM
1.530
+0.065 (4.44%)
After-hours: Jul 2, 2024, 7:30 PM EDT
Aditxt Revenue
Aditxt had revenue of $506.44K in the twelve months ending March 31, 2024, down -46.23% year-over-year. Revenue in the quarter ending March 31, 2024 was $79.68K, a -63.52% decrease year-over-year. In the year 2023, Aditxt had annual revenue of $645.18K, a decrease of -30.90%.
Revenue (ttm)
$506.44K
Revenue Growth
-46.23%
P/S Ratio
5.77
Revenue / Employee
$10,775
Employees
47
Market Cap
2.92M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 645.18K | -288.54K | -30.90% |
Dec 31, 2022 | 933.72K | 828.68K | 788.96% |
Dec 31, 2021 | 105.03K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Petros Pharmaceuticals | 4.69M |
INVO Bioscience | 4.25M |
Assure Holdings | 1.63M |
Helius Medical Technologies | 668.00K |
60 Degrees Pharmaceuticals | 569.86K |
ADTX News
- 5 days ago - Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare - PRNewsWire
- 21 days ago - Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter - PRNewsWire
- 6 weeks ago - Evofem Biosciences Announces Financial Results for the First Quarter of 2024 - PRNewsWire
- 2 months ago - CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules - Business Wire
- 2 months ago - Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules - Business Wire
- 3 months ago - Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD) - Business Wire
- 3 months ago - Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 - PRNewsWire
- 3 months ago - Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal - PRNewsWire